ReviewFrontiers in pharmacology2026
Catechins in stroke: multi-target mechanisms, preclinical evidence, and translational challenges.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Backgrounds: Stroke is a leading cause of death and disability, with limited therapeutic options available. Catechin is a natural polyphenolic compound that exhibits significant neuroprotective effects. Objectives: This review aims to summarize the pharmacokinetics of catechins, their neuroprotective mechanisms, preclinical evidence, and the translational challenges associated with both ischemic and hemorrhagic stroke. Methods: A structured literature search was conducted from 1985 to 2026 in PubMed, Web of Science, and Scopus, utilizing keyword combinations related to catechins and stroke. Results: Current preclinical research findings indicate that catechins can alleviate oxidative inflammation, modulate microglial polarization, inhibit apoptosis, and restore autophagic function. Additionally, they can maintain blood-brain barrier integrity and mitochondrial function, as well as promote angiogenesis and neurogenesis. These protective effects have been validated in experimental models of ischemic stroke, intracerebral hemorrhage, and subarachnoid hemorrhage. However, the existing mechanistic evidence regarding their neuroprotective effects is predominantly derived from studies on (-)-epigallocatechin-3-gallate (EGCG), while research on other catechin monomers, green tea extracts, or mixed polyphenol preparations remains relatively scarce. Conclusion: Catechins represent promising candidate drugs for stroke due to their multiple neuroprotective potentials. However, most preclinical evidence arises from pretreatment paradigms, which are confounded by heterogeneity in dosage, age, and experimental models. Additionally, the low bioavailability and narrow therapeutic window of catechins restrict their clinical translation. Future research should prioritize the development of nano-delivery systems, the optimization of dosing regimens, and the validation of findings in aged and comorbid models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.